In summary, our meta-analysis demonstrates that SGLT2 inhibitors significantly reduce the risk of AF/AFL but have no notable impact on the risk of VT, VF, and sinus bradycardia. This evidence concerns the gene SLC5A2 and atrial fibrillation.